Seres Therapeutics Inc (MCRB) Price Prediction & ForecastMCRBSeres Therapeutics Inc

Alphio's MCRB stock price prediction model matches the current Seres Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $5.21 (+0.53%). The 1-week path is $5.42 (+4.68%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Seres Therapeutics Inc is a good buy right now, primarily due to its recent financial turnaround, reporting a net income of $4.6 million in Q2 2026, which translates to $0.47 per share, a significant improvement from a net loss of $19.9 million in the same quarter last year. Additionally, the stock has shown a positive momentum with a 5-day change of +12.06% and an RSI of 66.737, indicating strong buying pressure. However, a key risk is the company's high forward P/E ratio of 10.82, which suggests that the stock may be overvalued if future earnings do not meet expectations.

Seres Therapeutics Inc (MCRB) last closed at $5.18, gaining +5.50%. These facts feed the 1-day and 1-week MCRB price prediction above.